search
Back to results

Fecal Microbiome Transplant

Primary Purpose

Clostridium Difficile, Inflammatory Bowel Disease, Crohn's Disease

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Fecal Microbiota Transplant
Sponsored by
Judith Kelsen
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Clostridium Difficile focused on measuring Fecal Microbiota transplant

Eligibility Criteria

3 Years - 21 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Diagnosis of Inflammatory Bowel Disease by colonoscopy, radiographic and clinic measures, as per standard protocol.
  2. Age ≥ 3 years old.
  3. Recurrent C. difficile or Moderate to Severe C. difficile.
  4. Satisfactory completion of the medical interview and physical exam conducted by a study team member
  5. Participants must be between 3 and 21 years of age (inclusive)
  6. Signed informed consent form, and assent (if applicable)

Exclusion Criteria:

  1. Patients <3 years old
  2. Patients with other co-morbid intestinal infectious processes
  3. Recipients with a history of severe (anaphylactic) food allergy
  4. If female, participants of childbearing potential (females aged 11 and older or those who have already begun menstruating) will be required to have a urine pregnancy test on the day of the FMT procedure. Patients who are pregnant will not be enrolled.
  5. Patients with severe IBD.
  6. Ongoing/anticipated antibiotic use for non-CDI indication
  7. Adverse event attributable to a previous FMT
  8. Patients with allergies to sodium chloride or glycerol, both ingredients Generally Recognized As Safe (GRAS)
  9. Any other condition for which the treating physician thinks the treatment may pose a health risk
  10. Predicted death within time period of follow-up
  11. Patients who are on supraphysiologic doses of corticosteroids

Sites / Locations

  • Children's Hospital of PhiladelphiaRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Other

Other

Arm Label

C. Difficile without IBD

C. Difficile with IBD

Arm Description

Fecal Microbiota transplant in pediatric patients with recurrent C. Difficile

Fecal Microbiota transplant in pediatric patients with recurrent C. Difficile with Inflammatory Bowel Disease

Outcomes

Primary Outcome Measures

Number of subjects with a recurrence of C. difficile (CDI)
The hypothesis is that FMT will be an effective therapy for patients with IBD and CDI, resulting in resolution of symptoms as compared to historical controls on antibiotic therapy.

Secondary Outcome Measures

Full Information

First Posted
December 16, 2015
Last Updated
April 4, 2023
Sponsor
Judith Kelsen
search

1. Study Identification

Unique Protocol Identification Number
NCT02636517
Brief Title
Fecal Microbiome Transplant
Official Title
Fecal Microbiome Transplant in Pediatric C. Difficile
Study Type
Interventional

2. Study Status

Record Verification Date
April 2023
Overall Recruitment Status
Recruiting
Study Start Date
December 2015 (undefined)
Primary Completion Date
December 2025 (Anticipated)
Study Completion Date
December 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Judith Kelsen

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Fecal Microbiota Transplant (FMT) in pediatric patients with recurrent C. Difficile with or without Inflammatory Bowel Disease (IBD) The aims of this study are to determine the safety and efficacy of FMT treatment in pediatric patients with recurrent or moderate to severe C. Difficile without (through an observational study) and with (through a clinical trial) Inflammatory Bowel Disease and to determine the effect of FMT on the gut microbiota through the use of 454 pyrosequencing before and after transplantation in these patients.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Clostridium Difficile, Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis
Keywords
Fecal Microbiota transplant

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
250 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
C. Difficile without IBD
Arm Type
Other
Arm Description
Fecal Microbiota transplant in pediatric patients with recurrent C. Difficile
Arm Title
C. Difficile with IBD
Arm Type
Other
Arm Description
Fecal Microbiota transplant in pediatric patients with recurrent C. Difficile with Inflammatory Bowel Disease
Intervention Type
Biological
Intervention Name(s)
Fecal Microbiota Transplant
Intervention Description
Fecal Microbiota transplant via colonoscopy, considered both a biologic and a drug
Primary Outcome Measure Information:
Title
Number of subjects with a recurrence of C. difficile (CDI)
Description
The hypothesis is that FMT will be an effective therapy for patients with IBD and CDI, resulting in resolution of symptoms as compared to historical controls on antibiotic therapy.
Time Frame
7 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
3 Years
Maximum Age & Unit of Time
21 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Diagnosis of Inflammatory Bowel Disease by colonoscopy, radiographic and clinic measures, as per standard protocol. Age ≥ 3 years old. Recurrent C. difficile or Moderate to Severe C. difficile. Satisfactory completion of the medical interview and physical exam conducted by a study team member Participants must be between 3 and 21 years of age (inclusive) Signed informed consent form, and assent (if applicable) Exclusion Criteria: Patients <3 years old Patients with other co-morbid intestinal infectious processes Recipients with a history of severe (anaphylactic) food allergy If female, participants of childbearing potential (females aged 11 and older or those who have already begun menstruating) will be required to have a urine pregnancy test on the day of the FMT procedure. Patients who are pregnant will not be enrolled. Patients with severe IBD. Ongoing/anticipated antibiotic use for non-CDI indication Adverse event attributable to a previous FMT Patients with allergies to sodium chloride or glycerol, both ingredients Generally Recognized As Safe (GRAS) Any other condition for which the treating physician thinks the treatment may pose a health risk Predicted death within time period of follow-up Patients who are on supraphysiologic doses of corticosteroids
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Judith Kelsen, MD
Phone
267-426-6822
Email
kelsen@chop.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Melissa Kennedy, MD
Phone
267-426-1495
Email
kennedym1@chop.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Judith Kelsen, MD
Organizational Affiliation
Children's Hospital of Philadelphia
Official's Role
Principal Investigator
Facility Information:
Facility Name
Children's Hospital of Philadelphia
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19104
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Judith Kelsen, MD
Phone
267-426-6822
Email
kelsen@chop.edu
First Name & Middle Initial & Last Name & Degree
Melissa Kennedy, MD
Phone
267-426-1495
Email
kennedym1@chop.edu

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Fecal Microbiome Transplant

We'll reach out to this number within 24 hrs